The Dog Days Are Back
Is it hot or what!? Whether you’re trying to catch a tan or stay cool, we have a fresh dose of weekly content in Editor’s choice. There are new possible treatments for both sickle cell disease and myelofibrosis this week, and we will also talk about this year’s NORD conference and a cancer survivor’s new project. You won’t want to miss this weeks hot topics.
[one_half]
[/one_half] [one_half_last]
Antibodies: The Key to Fighting Sickle Cell Anemia? Approval Could be Just Months Away
An antibody-style drug in development from Novartis has the potential to alleviate some of the worst complications of sickle cell disease—and this drug could get cleared a lot more quickly than you think.[/one_half_last] [one_half]
[/one_half] [one_half_last]
Catalysts for Change and Guidance for Growth: Terri’s Story
A cancer survivor uses her experience to form a new organization that allows patients and survivors to give back to their communities.
[/one_half_last] [one_half]
[/one_half] [one_half_last]
NORD 2019 Living Stronger Forum Highlights
In this story we talk about some of the highlights from our coverage of this year’s National Organization for Rare Disorders conference.
[/one_half_last]
[one_half]
.jpg)
[/one_half] [one_half_last]
Huntsman Lab Research Team Discovers that Selinexor May Benefit Myelofibrosis Patients Who have No Other Curative Options
Researchers discover a new viable treatment for patients suffering from myelofibrosis.
[/one_half_last]
[one_half]
